CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on April 24, 2025 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c) (the “Listing Rule”) as a result of its failure to timely file its Annual Report on Form 10-K for the annual period end ...

Qualigen and Marizyme have entered an MOU dated March 28, 2025. This is the logical next step in acquiring Marizyme, following on our co-marketing agreement established in 2024. Upon completion of full due diligence, we will proceed with the final structure and deal terms which will be subject to shareholder approval following the filing of an S4. There can be no assurance that any transaction will be completed or that definitive agreements will be executed. CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) ...

Market size expected to reach $4.7 billion in 2027 CARLSBAD, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”)announced today they will be the first investors participating in the 2025 bridge round of funding for NanoSynex. NanoSynex will be raising up to $500,000. “We are very excited to participate and be the first investors to commit in this round of funding for NanoSynex. The technology they are developing will help the world of Antimicrobial Susceptibi ...

New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life science company focused on developing platform treatments for adult and pediatric cancers, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $.001 per share QLGN The Nasdaq Capital Market of The Nasdaq Stock Market LLC Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ...

CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the sym ...

CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the "Company") announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed ...

New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the "Offering") of (i) 14,724,058 shares of common stock priced at $0.130 per share, with pre-funded warrants exercisable for 11,972,754 shares with respect to the registered direct offering for its client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the " ...

CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the "Company") today announced the closing of its previously announced public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a "Share," and collectively, the "Shares") at public offering price of $0.13 per Share and pre-funded warrants to purchase up to 11,972,754 Shares at a price of $0.129 per share with an exercise price of $0.001 per share (the "Pre-Funded Warrants"). The Pre ...

CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the "Company") today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a "Share," and collectively, the "Shares") at a public offering price of $0.13 per Share and pre-funded warrants to purchase up to 11,972,754 Shares at a price of $0.129 per prefunded warrant with an exercise price of $0.001 per share (the "Pre-Funded Warrants"). The Pre-Funded W ...